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4-7 years old and active life in children 8–11 years old in
mild BA did not differ comparing with healthy children
(36,75 against 35,9 marks and 30,16 against 29,71 marks
conformably) but decreased with worsening disease (30,1
and 26,77 in middle severe and severe BA). Mild and
middle severe BA impacted on quality of child’s life a lit-
tle but severe BA restricted child’s life considerably
(19,23–20,25 and 16,2 marks conformably). CONCLU-
SION: Analysis revealed considerable decreasing quality
of life in children with BA, restriction in physical, psych-
oemotional and social spheres of life. Questionnaire
adapted by V. Petrov and I. Smolenov was exact; that is
why this wellbeing questionnaire was able to use such
criterion of treatment effectiveness in children with BA.
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OBJECTIVE: To examine the health resource use by pa-
tients with chronic obstructive airway disease (COAD)
from the perspective of a public health organization.
METHODS: Seventy-one patients with exacerbation of
COAD admitted to the medical wards of a public hospi-
tal in Hong Kong during a six-week period were studied.
They were interviewed using a structured questionnaire
and their medical history was reviewed. During the inter-
view, patients’ background, level of disease knowledge
and their drug treatment were obtained. Direct medical
costs during hospitalization were estimated from their
hospital records. The annual direct medical costs due to
COAD were estimated from the number of COAD hospi-
tal admissions and the median cost of hospitalization of
our study patients. RESULTS: 72% percent of patients
attended regular follow-up visits for COAD but none at-
tended the rehabilitation program offered on an outpa-
tient basis. 85% of patients had used bronchodilator in-
halation therapy on a regular basis. The disease knowledge
of the study patients was generally poor. For the current
exacerbation, 42% of patients had visited private medi-
cal practitioners prior to admission. The median duration
of hospital stay was 5 days (range 3–33 days). There
were a total of 42,241 admissions per year due to COAD
in the whole territory. Average cost of hospitalization
was HK$3,632/day (1US$  7.8HK$). The annual hos-
pital cost for patients with COAD exacerbation was esti-
mated to be about HK$767 million, representing about
2.4% of the annual total health care budget in Hong
Kong. CONCLUSION: The cost of hospitalization of pa-
tients with COAD exacerbation was high. Patient knowl-
edge could be improved and outpatient rehabilitation
program could be further publicized.
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OBJECTIVE: To characterize the treatment and costs
associated to rhinitis in a managed care population.
METHODS: All subjects contained within PharMetric’s
Integrated Outcomes database possessing a diagnosis of
rhinitis (ICD-9-CM  477) and a prescription claim for a
rhinitis specific medication during 1997–1998 were eligi-
ble for study inclusion. Patients were required to have 12
months of data following the first (index) rhinitis diagno-
sis present. Patients were stratified according to the num-
ber of comorbid conditions (0 comorbidities, 1 comor-
bidity, 	 1 comorbidity). Measured conditions included
upper respiratory infections, sinusitis, asthma, bronchitis,
conjunctivitis, and otitis media. Patient demographics,
rhinitis specific charges, and comorbid conditions were
captured for each patient during the study period. RE-
SULTS: 202,426 patients met the inclusion criteria. The
mean age was 33.9 years (SD  17.7) and 61.4% were
female. The most commonly identified comorbid condi-
tions were upper respiratory infection (32.2%) and si-
nusitis (34.2%). The proportion of females increased
with the presence of comorbid conditions, as did pre-
scription therapy. The most common antihistamine was
loratadine, which was prescribed to approximately 57%
followed by fexofenadine (19%) and cetirizine (14%).
Nasal steroids were prescribed to over half of the sample
(58%). Mean rhinitis specific treatment charges for the
12 months following initial diagnosis range from $371
(SD  365) to $590 (SD  642) for patients with 2 or
more comorbidities. CONCLUSION: Rhinitis is a preva-
lent condition within this managed care population, asso-
ciated with substantial utilization of healthcare resources.
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Bronchial asthma is a chronic disease, having an increas-
ing prevalence and causes an increasing burden to the
health care. Understanding the drug costs and use of the
drug will help to rationalise the drug use. OBJECTIVES:
1) give a picture of asthma in Hungary concerning the ep-
idemiological data; 2) analyze the anti-asthma drug use
and costs in Hungary; 3) define the changes in the drug
use in hospitals which are specialised for asthma; 4) ana-
lyze the connection between the drug consumption data
and the epidemiological data. METHODS: The epidemi-
ological data was given by the Hungarian Pulmonologist
Association. Between 1989 and 1998 the drug consump-
